FDA approves treatment for chronic rhinosinusitis with nasal polyps

The U.S. Food and Drug Administration has approved the use of the monoclonal antibody Tezepelumab-ekko (Tespire; AstraZeneca/Amgen) to treat patients aged 12 years and older with chronic rhinosinusitis and nasal polyps.

The approval comes after positive results were reported in the Phase 3 WAYPOINT trial, according to a news report from the American Journal of Managed Care. The patients who received tezepelumab experienced clinically meaningful reductions in nasal polyp size, congestion, systemic corticosteroid dependence and sinus surgery compared with those who received placebo.

The FDA approval provides patients with inadequately controlled chronic rhinosinusitis with a novel treatment option to address persistent symptoms.

Read more: American Journal of Managed Care

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.